

CONTENTS

PREFACE xiii

CHAPTER 1. MOLECULAR MECHANISMS OF DRUG ACTION 1

Receptors 1

Binding Forces in the Drug-Receptor Interaction 3

Bond Types 3

Drug-Receptor Interaction as Resultant of the Several Bond Types 25

The Ionization of Drugs 25

Structure-Activity Relationships and the Conformation of the Receptor Surface 30

Methods of Studying Receptors 30

Drug-Protein Interactions as Models of Drug-Receptor Interactions 34

Acetylcholine and Congeners 40

The Polymethylene Bis-Methonium Series 44

The Morphinelike Analgesics 50

Congeners of the Adrenal Glucocorticoid Hormones 56

Congeners of the Pituitary Polypeptide Hormones 59

Cycloserine and the Inhibition of Bacterial Cell Wall Synthesis 63

Antibacterial Sulfonamides 66

Consequences of Drug-Receptor Interactions: Analysis of the Graded Dose-Response Relationship 70

Application of the Law of Mass Action 70

The Double-Reciprocal Plot 72

The Log Dose-Response Curve 77

Anomalous Antagonisms and Their Interpretation 88

Other Ways of Interpreting the Log Dose-Response Relationship 94

Drug Actions that are not Mediated Directly by Receptors 99

CHAPTER 2. THE ABSORPTION, DISTRIBUTION, AND ELIMINATION OF DRUGS 106

Introduction 106

Drug Absorption: Routes of Administration 108

Intravascular Administration 108

Intramuscular Administration 111

Subcutaneous Administration 111

Absorption of Drugs through the Skin 114

Inhalation of Drugs 115

Administration of Drugs by the Enteral Route 119

Drug Distribution 130

Apparent Volumes of Distribution 130

The Binding of Drugs to Plasma Proteins 136

Passage of Drugs across Biologic Membranes 145

Passage of Drugs into the Central Nervous System 160
Passage of Drugs across the Placenta 179

Drug Elimination: The Major Routes 194

Renal Excretion of Drugs 194
Extracorporeal Dialysis 202
Biliary Excretion of Drugs 203

CHAPTER 3. DRUG METABOLISM 206

Introduction 206

Methods of Studying Drug Metabolism 210

Separation of Metabolites 211
Quantitative Estimation of Metabolites 216

Chemical Pathways of Drug Metabolism 218

The Liver Microsomal Drug-Metabolizing System 218
Drug Oxidations that are not Mediated by the Liver Microsomal System 232
Reduction 236
Hydrolysis 237
Synthetic (Conjugation) Reactions 238

Inhibition of Drug Metabolism 249

SKF 525A 249
Disulfiram 253
Monoamine Oxidase Inhibitors 257

Stimulation and Depression of Drug Metabolism 259

Species Differences and Genetic Variation in Drug Metabolism 266

Effects of Age upon Drug Metabolism 274

CHAPTER 4. THE TIME COURSE OF DRUG ACTION 280

Rate of Drug Absorption 280

Rate of Drug Elimination 283

Zero-Order Absorption, First-Order Elimination: The Plateau Principle 292

Derivation of the Principle and Its Application to Constant Infusions 292
Dosage Regimens 300
Drug Accumulation and Toxicity 309
Kinetics of Changes in Enzyme Levels 313

First-Order Absorption, First-Order Elimination: Kinetics of Drug Levels after Single Doses 317

Kinetics of the Uptake and Distribution of Drugs Administered by Inhalation:

An Application of the Plateau Principle to Anesthetic Gases 323
Introduction 323
Equilibrium in Clinical Anesthesia 327
Rate of Equilibration of Blood and Body Water 329

- Influence of Body Fat* 337
Speed of Induction and Recovery in Clinical Anesthesia 339

CHAPTER 5. DRUG TOXICITY 343

- Introduction** 343
The Evaluation of Drug Toxicity in Lower Animals and in Man 350
Treatment of Toxicity 377
Principles of Nonspecific Therapy 377
Principles of Antidotal Treatment 384

CHAPTER 6. DRUG IDIOSYNCRASY AND PHARMACOGENETICS 429

- Introduction** 429
Abnormally Prolonged Drug Effect 434
Succinylcholine Hydrolysis 434
Hereditary Methemoglobinemia 441
Slow Metabolism of Isoniazid 443
Increased Sensitivity to Drug 444
Abnormal Hemoglobins 444
Novel Drug Effect 444
Primaquine Sensitivity 444
Porphyria 453
Decreased Responsiveness to Drug 457
Coumarin Resistance 457
Vitamin D-Resistant Rickets 460
Inability to Taste Phenylthiourea 461
Juvenile Pernicious Anemia 465
Resistance to Succinylcholine 465
Atropine Resistance (Rabbits) 466
Insulin Resistance (Mice) 467
Racial Differences in Drug Response 467
Abnormal Distribution of Drug 467
Copper (Wilson's Disease) 467
Iron (Primary Hemochromatosis) 469
Increased or Decreased Thyroxine-Binding Globulin 472
Differences in Use of and Response to Psychotropic Drugs 474

CHAPTER 7. DRUG ALLERGY 476

- Introduction** 476
Immunologic Basis of Drug Allergy 479
Covalently Bonded Drug-Protein Conjugates 479
Affinity Labeling 489

Drug Allergy in Man 490

- Manifestations of Drug Allergy 491*
- Frequency of Allergic Reactions to Drugs 495*
- Tests for Predicting Drug Allergies 503*
- Desensitization 505*
- Management of Drug Allergies 506*

CHAPTER 8. DRUG RESISTANCE 508**Origin of Acquired Drug Resistance 508**

- The Mutation-Selection Mechanism 508*
- Evidence for the Mutational Origins of Drug Resistance 509*
- Patterns of Emergence and Spread of Drug Resistance 513*

Biochemical Mechanisms of Drug Resistance 518

- Mechanism 1. Decreased Intracellular Drug Level 518*
- Mechanism 2. Increased Destruction of Drug 523*
- Mechanism 3. Decreased Conversion of Drug to a More Active Compound 526*
- Mechanism 4. Increased Concentration of Metabolite Antagonizing the Drug Action 530*
- Mechanism 5. Increased Amount of Target Enzyme 530*
- Mechanism 6. Decreased Requirement for Product of Drug-Sensitive Enzyme (Hypothetical) 533*
- Mechanism 7. Alternative Metabolic Pathway Bypassing the Drug-Sensitive Reaction (Hypothetical) 534*
- Mechanism 8. Decreased Relative Affinity of Enzyme for Drug Compared with Substrate 534*

Streptomycin Dependence 545

- Protein Synthesis and the Genetic Code 545*
- Disturbance of Translation by Streptomycin 549*
- Phenotypic Suppression and the "Misreading" Hypothesis 552*

Selection of Drug-Resistant Cells in Animals and Man 554**CHAPTER 9. DRUG TOLERANCE AND PHYSICAL DEPENDENCE 558****Tolerance by Indirect Mechanisms 558**

- Reduction of the Effective Drug Concentration 559*
- Homeostatic Adjustments Antagonizing the Drug Action 561*

Tolerance at the Cellular Sites of Drug Action 564

- Acute Tolerance (Tachyphylaxis) 565*
- Tolerance and Physical Dependence in the Central Nervous System 578*

CHAPTER 10. CHEMICAL MUTAGENESIS 618**Introduction 618****Base Pair Transformations 628**

Frame Shift Mutations 640

Chromosome Breakage 647

Metaphase Poisoning (Spindle Inactivation) 653

Chemical Mutagenesis in Animals and Man 657

The Human Germ Line 657

Some Common Methods of Testing Mutagenicity in Animals 660

Evaluation of the Hazards of Chemical Mutagens in Man 663

CHAPTER 11. CHEMICAL CARCINOGENESIS 669

Mechanism of Action of Chemical Carcinogens 670

Methods of Experimentation 670

Initiation and Promotion 673

Cancer as a Genetic Abnormality of Somatic Cells 677

Molecular Interactions of Carcinogens with Cell Constituents 680

The Principal Groups of Chemical Carcinogens 685

Polycyclic Hydrocarbons 685

Amines 689

Alkylating Agents 698

Alkylation and Arylation in the Carcinogenic Process 701

Carcinogenic Hazards in the Human Environment 702

Epidemic Outbreaks of Cancer 702

Smoking and Lung Cancer 704

The Problem of Eliminating and Excluding Carcinogens from the Environment 708

CHAPTER 12. CHEMICAL TERATOGENESIS 711

Experimental Teratogenesis 713

Methods 713

Selectivity of Action in Teratogenesis 713

Genetic Influences 715

Sensitive Periods 717

Specificity and Variety of Teratogens 720

Teratogenesis in Man 724

Congenital Malformations in Human Populations 724

Accidental Human Exposure to Teratogens 726

Lessons of the Thalidomide Catastrophe 729

CHAPTER 13. DRUG DEVELOPMENT 735

Introduction 735

Qualitative and Quantitative Estimation of Drug Action 738

Screening 739

Bioassay 746

Methods of Developing New Drugs	751
<i>Purification of Drugs from Natural Sources</i>	751
<i>Modification of Chemical Structure</i>	763
<i>Synthesis of New Drugs</i>	777
CHAPTER 14. THE SELECTION OF DRUGS FOR CLINICAL USE	792
Steps Leading to the Clinical Trial	792
Drug Evaluation in Man: The Clinical Trial	794
<i>Placebo Controls and Concurrent Comparisons</i>	794
<i>Randomization</i>	799
<i>Blind Designs</i>	801
<i>Two Trials with Antihistamines: An Illustrative Contrast</i>	803
<i>Sequential Trials</i>	808
<i>Critical Appraisal of Reports on Clinical Trials</i>	814
<i>Ethics of Human Experimentation</i>	815
Use and Misuse of Drugs	819
<i>Legal Controls over Drug Availability</i>	819
<i>Self-Medication and Iatrogenic Disease</i>	825
<i>Drug Nomenclature and Drug Prices</i>	827
Sources of Information about Drugs	831
<i>Official Compendiums</i>	832
<i>Unofficial Compendiums</i>	834
<i>Critical Evaluations</i>	835
<i>Advertising and Promotion</i>	838
APPENDIX I. PRINCIPLES OF PRESCRIBING	841
APPENDIX II. LIST OF ABBREVIATIONS AND SYMBOLS	847
INDEX	849